Endocrinology, Vol 127, 3087-3095, Copyright © 1990 by Endocrine Society

ARTICLES

Mechanisms of impaired growth hormone secretion in genetically obese Zucker rats: roles of growth hormone-releasing factor and somatostatin

GS Tannenbaum, M Lapointe, W Gurd and JA Finkelstein
Neuropeptide Physiology Laboratory, McGill University Montreal Children's Hospital Research Institute, Quebec, Canada.

GH secretion is markedly blunted in obesity; however, the mechanism(s) mediating this response remains to be elucidated. In the present study we examined the involvement of the two hypothalamic GH-regulatory hormones, GH-releasing factor (GRF) and somatostatin (SRIF), using the genetically obese male Zucker rat. Spontaneous GH, insulin, and glucose secretory profiles obtained from free moving, chronically cannulated rats revealed a marked suppression in amplitude and duration of GH pulses in obese Zucker rats compared to their lean littermates (mean 6- h plasma GH level, 3.9 +/- 0.4 vs. 21.5 +/- 3.8 ng/ml; P less than 0.001). Obese rats also exhibited significant hyperinsulinemia in the presence of normoglycemia. The plasma GH response to an iv bolus of 1 microgram rat GRF-(1-29)NH2, administered during peak and trough periods of the GH rhythm, was significantly attenuated in obese rats at peak (137.4 +/- 26.1 vs. 266.9 +/- 40.7 ng/ml; P less than 0.02), although not at trough, times. Passive immunization of obese rats with a specific antiserum to SRIF failed to restore the amplitude of GH pulses to normal values; the mean 6-h plasma GH level of obese rats given SRIF antiserum was not significantly different from that of obese rats administered normal sheep serum. Both pituitary wet weight and pituitary GH content and concentration were reduced in the obese group. Measurement of hypothalamic GRF immunoreactivity revealed a significant (P less than 0.05) reduction in the mediobasal hypothalamic GRF content in obese rats (503.2 +/- 60.1 pg/fragment) compared to that in lean controls (678.1 +/- 50.2 pg/fragment), although no significant difference was observed in hypothalamic SRIF concentration. Peripheral SRIF immunoreactive levels were significantly (P less than 0.01) elevated in both the pancreas and stomach of obese rats. These results demonstrate that the genetically obese Zucker rat exhibits 1) marked impairment in both spontaneous and GRF-induced GH release, which cannot be reversed by SRIF immunoneutralization, 2) significant reduction in pituitary GH concentration, 3) depressed hypothalamic GRF content, and 4) elevated gastric and pancreatic, but not hypothalamic, SRIF levels. The findings suggest that the defect in pituitary GH secretion observed in the genetically obese Zucker rat is due, at least partially, to insufficient stimulation by hypothalamic GRF, and that SRIF does not play a significant role.

This article has been cited by other articles:

				R. M. Luque, Z. H. Huang, B. Shah, T. Mazzone, and R. D. Kineman Effects of leptin replacement on hypothalamic-pituitary growth hormone axis function and circulating ghrelin levels in ob/ob mice Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E891 - E899. [Abstract] [Full Text] [PDF]

				R. M. Luque and R. D. Kineman Impact of Obesity on the Growth Hormone Axis: Evidence for a Direct Inhibitory Effect of Hyperinsulinemia on Pituitary Function Endocrinology, June 1, 2006; 147(6): 2754 - 2763. [Abstract] [Full Text] [PDF]

				S. V Haijma, P S. van Dam, W. R de Vries, I. Maitimu-Smeele, C. Dieguez, F. F Casanueva, and H. P F Koppeschaar The GHRH/GHRP-6 test for the diagnosis of GH deficiency in elderly or severely obese men Eur. J. Endocrinol., April 1, 2005; 152(4): 575 - 580. [Abstract] [Full Text] [PDF]

				S. Lall, N. Balthasar, D. Carmignac, C. Magoulas, A. Sesay, P. Houston, K. Mathers, and I. Robinson Physiological Studies of Transgenic Mice Overexpressing Growth Hormone (GH) Secretagogue Receptor 1A in GH-Releasing Hormone Neurons Endocrinology, April 1, 2004; 145(4): 1602 - 1611. [Abstract] [Full Text] [PDF]

				L. Gianotti, S. Pivetti, F. Lanfranco, F. Tassone, F. Navone, E. Vittori, R. Rossetto, C. Gauna, S. Destefanis, S. Grottoli, et al. Concomitant Impairment of Growth Hormone Secretion and Peripheral Sensitivity in Obese Patients with Obstructive Sleep Apnea Syndrome J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 5052 - 5057. [Abstract] [Full Text] [PDF]

				P. Rietschel, C. Hadigan, C. Corcoran, T. Stanley, G. Neubauer, J. Gertner, and S. Grinspoon Assessment of Growth Hormone Dynamics in Human Immunodeficiency Virus-Related Lipodystrophy J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 504 - 510. [Abstract] [Full Text]

				M. Maccario, F. Tassone, L. Gianotti, F. Lanfranco, S. Grottoli, E. Arvat, E. E. Muller, and E. Ghigo Effects of Recombinant Human Insulin-Like Growth Factor I Administration on the Growth Hormone (GH) Response to GH-Releasing Hormone in Obesity J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 167 - 171. [Abstract] [Full Text]

				E. E. Muller, V. Locatelli, and D. Cocchi Neuroendocrine Control of Growth Hormone Secretion Physiol Rev, April 1, 1999; 79(2): 511 - 607. [Abstract] [Full Text] [PDF]

				G. S. Tannenbaum, W. Gurd, and M. Lapointe Leptin Is a Potent Stimulator of Spontaneous Pulsatile Growth Hormone (GH) Secretion and the GH Response to GH-Releasing Hormone Endocrinology, September 1, 1998; 139(9): 3871 - 3875. [Abstract] [Full Text] [PDF]

				W. Liao, B. Angelin, and M. Rudling Lipoprotein Metabolism in the Fat Zucker Rat: Reduced Basal Expression but Normal Regulation of Hepatic Low Density Lipoprotein Receptors Endocrinology, August 1, 1997; 138(8): 3276 - 3282. [Abstract] [Full Text] [PDF]

				E. Melian, B. Velasco, R. Barrios, and F. Sanchez-Franco Basal and Growth Hormone-Induced Hepatic Messenger Ribonucleic Acid Expression of Insulin-Like Growth Factor-I (IGF-I) and IGF-Binding Protein-3 Is Independent of Hyperinsulinemia and Increased Energy Status in the Genetically Obese Zucker Rat Endocrinology, March 1, 1997; 138(3): 1066 - 1071. [Abstract] [Full Text] [PDF]